Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Integration of Functional Ex Vivo Drug Testing and Molecular Profiling Reveals Novel Vulnerabilities in CMML

Tea Pemovska, PhD, Gregory Ian Vladimer, PhD, Vitaly Sedlyarov, PhD, Emir Hadzijusufovic, DVM, Karoline Veronika Gleixner, MD, Alexandra Keller, MSc, Berend Snijder, PhD, Nikolaus Krall, PhD, Oscar Lopez de la Fuente, BSc, Mathias A Schneeweiss, MD, Wolfgang R. Sperr, MD, Paul Knöbl, MD PhD, Klaus Geissler, MD, Philipp Bernhard Staber, MD PhD, Ulrich Jaeger, MD, Peter Valent, MD, Giulio Superti Furga, PhD

Blood (2017) 130 (Supplement 1): 4227.

https://doi.org/10.1182/blood.V130.Suppl_1.4227.4227

Published: 2017

Journal Articles

Methotrexate Is a Suppressor of JAK/STAT Pathway Activation Which Inhibits JAK2V617F Induced Signalling

Sally J Thomas, BA BM BCh MRCP(UK), Katherine Fisher, MSci DPhil, Stephen Brown, BSc PhD, John A Snowden, MD FRCP, FRCPath, Sarah Danson, BMedSci BMBS MSc PhDFRCP, Martin Zeidler, BSc DPhil

Blood (2014) 124 (21): 4577.

https://doi.org/10.1182/blood.V124.21.4577.4577

Published: 2014

Journal Articles

Phase IIB Trial of Aminopterin in Multiagent Therapy for Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) at High Risk of Relapse.

Peter D. Cole, MD, Richard A. Drachtman, MD, Angela K. Smith, Margaret Masterson, MD, John Glod, Md, PhD, Barton A. Kamen, MD, PhD

Blood (2006) 108 (11): 1860.

https://doi.org/10.1182/blood.V108.11.1860.1860

Published: 2006

Journal Articles

Pralatrexate (PDX) Produces Durable Complete Remissions in Patients with Chemotherapy Resistant Precursor and Peripheral T-Cell Lymphomas: Results of the MSKCC Phase I/II Experience.

Owen A. O’Connor, MD, PhD, P.A. Hamlin, MD, J. Gerecitano, MD, PhD, C.S Portlock, MD, A. Noy, MD, C. Moskowitz, MD, D.J. Straus, MD, D. Sarasohn, MD, O. Dumetrescu, MD, J. Pappanicolou, RN, E. Neylon, A.D. Zelenetz, MD, M.E. Saunders, MD, D.R. Mould, PhD, M. Fleischer, PhD, F. Sirotnak, PhD, S.M. Horwitz, MD

Blood (2006) 108 (11): 400.

https://doi.org/10.1182/blood.V108.11.400.400

Published: 2006

Journal Articles

Aminopterin Can Replace Methotrexate for Children with Newly Diagnosed Acute Lymphoblastic Leukemia without Excessive Toxicity.

Peter D. Cole, MD, Richard A. Drachtman, MD, Margaret Masterson, MD, Angela Shenkerman, APN, Angela K. Smith, Benadette Makori, Barton A. Kamen, MD, PhD

Blood (2004) 104 (11): 1950.

https://doi.org/10.1182/blood.V104.11.1950.1950

Published: 2004

NARROW

Integration of Functional Ex Vivo Drug Testing and Molecular Profiling Reveals Novel Vulnerabilities in CMML

Methotrexate Is a Suppressor of JAK/STAT Pathway Activation Which Inhibits JAK2V617F Induced Signalling

Phase IIB Trial of Aminopterin in Multiagent Therapy for Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) at High Risk of Relapse.

Pralatrexate (PDX) Produces Durable Complete Remissions in Patients with Chemotherapy Resistant Precursor and Peripheral T-Cell Lymphomas: Results of the MSKCC Phase I/II Experience.

Aminopterin Can Replace Methotrexate for Children with Newly Diagnosed Acute Lymphoblastic Leukemia without Excessive Toxicity.

Email alerts

ASH Publications

American Society of Hematology

Integration of Functional Ex Vivo Drug Testing and Molecular Profiling Reveals Novel Vulnerabilities in CMML

Methotrexate Is a Suppressor of JAK/STAT Pathway Activation Which Inhibits JAK2V617F Induced Signalling

Phase IIB Trial of Aminopterin in Multiagent Therapy for Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) at High Risk of Relapse.

Pralatrexate (PDX) Produces Durable Complete Remissions in Patients with Chemotherapy Resistant Precursor and Peripheral T-Cell Lymphomas: Results of the MSKCC Phase I/II Experience.

Aminopterin Can Replace Methotrexate for Children with Newly Diagnosed Acute Lymphoblastic Leukemia without Excessive Toxicity.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only